We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Christopher Posner, President and CEO of Cara Therapeutics Inc. (NASDAQ:CARA), a small-cap biotech company with a market capitalization of $23.22 million, recently sold shares of the company's common ...

Shares of Cara (NASDAQ:CARA) opened at $4.18 on a split-adjusted basis, later hitting a low of $4.15 and a high of $5.67.The stock recently sold for $5.64 at around 2:30 p.m. ET. The reverse stock ...

Cara Therapeutics is entering an all-stock deal to combine with private, clinical-stage biopharmaceutical company Tvardi Therapeutics. Tvardi will merge with a subsidiary of Cara under the terms ...

The company's stock will begin trading on a split-adjusted basis when markets open on Tuesday, December 31, 2024, under the existing ticker "CARA" but with a new CUSIP number, 140755 208.

Cara Therapeutics (CARA) announced that a 1-for-12 reverse stock split of its outstanding shares of common stock and reduction in the total number of authorized shares of its common stock from ...

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting ...

Following this transaction, Posner holds 13,692 shares of Cara Therapeutics. The reported shares reflect a 1-for-12 reverse stock split that occurred on December 30, 2024. With the company's next ...